Document is current
Any future updates will be listed below
-
Authors
Gupton, Stephanie E. https://orcid.org/0000-0002-4222-4622
McCarthy, Elizabeth A.
Markert, M. Louise
- License Information
-
More Information
Article History
Received: 10 February 2021
Accepted: 14 April 2021
First Online: 18 May 2021
Declarations
:
: Cultured thymus tissue implantation (CTTI) is an investigational product implanted into patients under an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Dr. Markert is the “sponsor” of the investigations. Dr. Markert developed the technology for CTTI. Duke has licensed the technology to Enzyvant Therapeutics GmbH. Dr. Markert and Duke have received royalties from Enzyvant. Portions of Dr. Markert’s and her research team’s salaries are being paid by funding from Enzyvant. If the technology is commercially successful in the future, Dr. Markert and Duke may benefit financially. The salary and other items needed to create CTTI are paid at cost by insurance.There is no conflict of interest to disclose by Gupton and McCarthy.
